Administration of hepatic stimulatory substance alone or with other liver growth factors does not ameliorate acetaminophen-induced liver failure

Antonio Francavilla, Alessandro Azzarone, Guiseppe Carrieri, Umberto Cillo, Daid Van Thiel, Vladimir Subbottin, Thomas E. Starzl

Research output: Contribution to journalArticle

Abstract

Sixty-two beagle dogs were given three doses of acetaminophen over a period of 24 hr in a fulminant liver failure model that is 70% lethal in 72 hr. Treatment of the animals with hepatic stimulatory substance alone or in a mixture with insulin, transforming growth factor-α and insulin-like growth factor II had no effect on mortality. Evidence of maximum regeneration with a mitotic index 20 to 25 times resting was the same in treated and untreated animals. Similarly, the biochemical and hematological indexes of liver injury were unaffected by therapy. These studies illustrate the futility of treating fulminant liver failure with exogenous growth factors that apparently are already present in large amounts in the natural response to liver injury. The results suggest that on-going liver injury by mechanisms other than lack of growth factors is the central problem of fulminant liver failure. If so, provision of regeneration-stimulating substance is an inappropriate therapeutic strategy.

Original languageEnglish
Pages (from-to)429-433
Number of pages5
JournalHepatology
Volume17
Issue number3
Publication statusPublished - Mar 1993

    Fingerprint

ASJC Scopus subject areas

  • Hepatology

Cite this

Francavilla, A., Azzarone, A., Carrieri, G., Cillo, U., Van Thiel, D., Subbottin, V., & Starzl, T. E. (1993). Administration of hepatic stimulatory substance alone or with other liver growth factors does not ameliorate acetaminophen-induced liver failure. Hepatology, 17(3), 429-433.